Search

【目的】基于普通经直肠超声（ERUS）、剪切波弹性成像（SWE）和多排螺旋CT的多模态影像组学分 析，并整合临床指标建立直肠癌淋巴结转移的预测模型。【方法】从2015年4月至2016年11月，93名直肠癌患 者纳入研究。患者行ERUS及SWE检查、多排螺旋CT平扫及增强扫描，并分析图像获得影像组学参数，所有病 例均接受了根治性手术切除并行病理检查。利用回归分析筛选出来的临床及实验室指标、US评分及CT评分， 建立综合预测模型，计算一致性指数（C-index），并与传统影像学标准进行比较。【结果】回归结果显示US指标 中淋巴结长径、肿物占据肠腔环周情况、uT分期、肿物弹性对比度、淋巴结最大杨氏模量、淋巴结弹性方差是影 响直肠癌淋巴结转移的危险因素。CT平扫及增强指标中，淋巴结数量、淋巴结短径和静脉期淋巴结最小CT值 是预测有无淋巴结转移的影响因素。利用性别、年龄、CEA、US评分及CT评分5个指标建立nomogram预测模型， 结果显示Nomogram的C-index为0.878。标准曲线显示nomogram预测效果与淋巴结转移的实际情况一致性较好。 与传统的以淋巴结长径作为诊断标准比较（US 为0.691，CT 为0.749），该预测模型的C-index 有明显提高（US 为 0.79，CT为0.83）。【结论】利用多模态影像组学（ERUS、SWE和多排螺旋CT）建立的可视化模型能评估直肠癌及淋 巴结的生物学特征，与传统诊断标准及单模态检查比较，该模型对直肠癌淋巴结转移的预测准确性均有提高。

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Machine Tool & Hydraulics is the property of Guangzhou Mechanical Engineering Research Institute (GMERI) and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objective To determine the effect of the Neuregulin-1 and its receptor ErbB4（NRG1-ErbB4） polymorphisms on focal epilepsy. Methods Three single nucleotide polymorphisms （SNPs） of NRG1 gene and three single nucleotide polymorphisms （SNPs） of ErbB4 gene in 70 patients with focal epilepsy and 64 healthy persons were analyzed by the PCR-SnapShot genotyping methods.The samples were all from the First Affiliated Hospital of Kunming Medical University from March to July, 2020. Results It was found that focal epilepsy was correlated with polymorphism of NRG1 （SNP rs35753505, T > C）, the distribution of genotype （P = 0.007） and allele （P = 0.005） of NRG1 （SNP rs35753505, T > C） was statistically significant （P < 0.005）. Meanwhile, ErbB4 gene polymorphisms of NRG1 downstream receptors was analyzed firstly, and two SNPs was found to be associated with focal epilepsy, ErbB4 SNP（rs839523, P = 0.026） and its allele （P = 0.013）, ErbB4 SNP（rs707284, P = 0.038） and its allele （P = 0.018）. However, no statistically significant association was found between NRG1（rs6994992, rs62510682）, ErbB4（rs7598440） polymorphisms and focal epilepsy. Conlusions The susceptibility of focal epilepsy carrying NRG1（SNP, rs35753505） and ErbB4（rs839523, rs707284） mutation homozygous has increased. NRG1-ErbB4 polymorphisms might play an important role together in the susceptibility to partial epilepsy. [ABSTRACT FROM AUTHOR]

Copyright of Modern Food Science & Technology is the property of Editorial Office of Modern Food Science & Technology and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

OBJECTIVE: To investigate the establishment and application of clinical pathway pharmacy evaluation system in the First Affiliated Hospital of Kunming Medical University(hereinafter referred to as "our hospital"). METHODS: Based on the literature research, Delphi’s method was used to draw up the rational drug evaluation system of clinical pathway from the aspects of safety, effectiveness, rationality and economy of drug use. Two questionnaires were made to 30 experts nationwide and the results were analyzed, and ultimately the clinical pathway rational drug evaluation system of our hospital was establish. According to the system, the clinical route of medication for bullous zoster in our hospital was evaluated. RESULTS: After two rounds of questionnaires, the expert’s positive coefficient was 100%, the authority coefficient was 0.805 and 0.830 respectively. The coordination coefficients of the first-level indicators were 0.537 and 0.476 respectively(P<0.01). The coordination coefficients of the second-level indicators were respectively 0.334 and 0.311(P<0.01). Finally, the drug evaluation system of clinical pathways including 4 first-level indicators and 14 second-level indicators was established. The system was used to evaluate the clinical pathway of blisters, the results showed that the dose, interval and course of treatment, route of administration, categories of antibiotics, application time of antibiotics, application rate of antibiotics, average length of stay, total treatment cost, proportion of average drug cost and essential drug cost in patients in the trial group with implementation the clinical pathway were significantly significantly lower than that of the control group without clinical pathway, and the differences were statistically significant(P<0.05). CONCLUSIONS: The reliability of the clinical pathway pharmacy evaluation system in our hospital is relatively high, which is basically recognized by experts and can be used as an effective tool for the evaluation of clinical pathway drug use. [ABSTRACT FROM AUTHOR]

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Progress in Modern Biomedicine is the property of Publishing House of Progress in Modern Biomedicine and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)